The present invention relates generally to apparatus, methods, and systems for providing brachytherapy to a human or other mammalian body, and more particularly to expandable apparatus for performing brachytherapy treatment within tissue, e.g., within breast tissue and/or within a body cavity, and to methods for performing brachytherapy using such apparatus.
Brachytherapy is a type of radiation therapy used to treat malignant tumors, such as cancer of the breast or prostate. In general, brachytherapy involves positioning a radiation source directly into target tissue, which may include a tumor and/or tissue surrounding a cavity or void, which may contain potentially cancerous cells (such as a cavity or void created by removing a tumor).
Brachytherapy is often divided into two categories: high dose rate (HDR) and low dose rate (LDR) brachytherapy. In HDR brachytherapy, a high activity radiation source is placed into target tissue, often via a previously implanted catheter, for a short period of time, e.g., lasting from several seconds to a few minutes. In contrast, LDR brachytherapy places a low activity radiation source into the target tissue for a longer, sometimes indefinite, period of time.
Both forms of brachytherapy have advantages. For instance, HDR brachytherapy provides higher radiation levels delivered over a shorter dose delivery period. LDR brachytherapy, on the other hand, utilizes lower activity radiation sources. The energy field of the LDR radiation source results in a measured and localized dose of radiation delivered to target tissue, e.g., a tumor, gland, or other tissue surrounding a cavity or void. However, the energy field thereafter decays to avoid excessive exposure of nearby healthy tissue.
Due in part to the lower activity of LDR radiation sources, LDR brachytherapy may provide various advantages. For example, for healthcare workers, exposure precautions for LDR brachytherapy may be less stringent than those for HDR brachytherapy. Also, there are radiobiological advantages of LDR brachytherapy over HDR brachytherapy (e.g., the dose rate effect), which may lead to better sparing of normal tissue during treatment. Moreover, for patients, the relatively longer implantation period associated with LDR brachytherapy may result in fewer visits to a healthcare facility over the course of radiation treatment, as compared to HDR brachytherapy where patients must return to the healthcare facility for each fraction of radiation delivered, which, for breast brachytherapy, may typically include eight to ten (8-10) fractions.
Common radiation sources used in LDR brachytherapy include radioactive isotopes such as Palladium (Pd)-103, Iodine (I)-125, Gold (Au)-198, and Iridium (Ir)-192. While the size and shape of the isotopes may vary, they may be provided in a standardized size of cylindrically shaped capsules that are approximately the size of a grain of rice, e.g., about 0.8 millimeter in diameter and about 4.5 millimeters in length, and are often referred to as “seeds.”
LDR seeds are often delivered through needles using a guide template. The guide template may include a matrix of holes that guide the longitudinal advancement of the needles to ensure their proper position relative to the target tissue. Once the needles are properly located in the target tissue, the seeds may be deposited along the longitudinal axis of each needle, after which the needles may be withdrawn.
Current brachytherapy implementations have potential drawbacks. For example, LDR seeds are typically left indwelling and free floating within the target tissue and are, therefore, susceptible to migration. Moreover, once implanted, LDR seeds are generally not considered removable or repositionable. LDR brachytherapy may also require careful dose distribution calculations and seed mapping before, and often during, seed implantation. Such calculation and mapping may allow effective radiation delivery to the target tissue volume, while minimizing radiation to surrounding healthy tissue (e.g., the urethra and rectum, for example, in prostate brachytherapy). Yet, while such dose calculation and seed mapping techniques are effective, problems may exist, such as potentially significant variability in accuracy of seed placement among different clinicians.
Yet another issue with conventional LDR brachytherapy techniques is that they may require the radioactive seeds to be manipulated individually at the time of implantation, which may be a time-consuming process. Moreover, conventional LDR delivery needles are generally limited to delivering the seeds linearly (along a relatively straight line). Thus, to achieve a desired therapy profile, numerous implants (e.g., including about 50-100 seeds, as are common with prostate brachytherapy) are often required, in conjunction with potentially complex dose distribution and mapping techniques and equipment.
The present invention is generally directed to apparatus, systems, and methods for delivering brachytherapy to a localized target tissue region. While the apparatus, systems, and methods described herein may be useful in treating most any area of the body, an exemplary application is treating breast tissue, e.g., breast tumors or lumpectomy cavities. For example, the apparatus, systems, and methods may be used to place and remove a localized radiation source for both neoadjuvant and post-excisional treatment.
In accordance with one embodiment, a brachytherapy treatment apparatus is provided that includes an elongate body including a proximal end and a distal end sized for introduction into a tract through tissue. A plurality of elongate members may be provided on the distal end including pathways for receiving a source of radiation therealong, the elongate members being movable from a collapsed configuration for introduction through a tissue tract to a target location, and an expanded configuration. A source of radiation may be introduceable along the pathways for delivering radiation to the target location.
In accordance with another embodiment, a brachytherapy treatment apparatus is provided that includes an elongate core member including a proximal end and a distal end configured for introduction into a tract through tissue; a distal hub coupled to the distal end of the core member; a proximal hub on the proximal end of the core member and movable axially relative to the distal hub; and a plurality of elongate members coupled to the proximal and distal hubs and extending between the proximal and distal ends of the core member, the elongate members movable from a collapsed configuration for introduction through a tissue tract to a target location, and an expanded configuration when the proximal hub is directed distally relative to the distal hub, the elongate members comprising pathways for receiving a source of radiation therealong.
In one embodiment, the core member may include first and second telescoping tubes, the first tube coupled to the proximal hub and the second tube coupled to the distal hub such that rotation of the first tube relative to the second tube causes the proximal hub to move distally to direct the elongate members towards the expanded configuration.
In another embodiment, the core member may include features that limit distal movement of the proximal hub, e.g., to prevent overexpansion of the elongate members in the expanded configuration. For example, the core member may include first and second telescoping tubes, the first tube coupled to the proximal hub and the second tube coupled to the distal hub such that rotation of the first tube relative to the second tube causes the proximal hub to move distally to direct the elongate members towards the expanded configuration, and the first and second tubes may be telescopingly coupled by mating threads. The threads may be disengaged when the first tube is rotated sufficiently to direct the elongate members to the expanded configuration, thereby limiting further distal movement of the proximal hub.
In yet another embodiment, the apparatus may include a release mechanism, e.g., on the core member and/or the proximal hub, for disengaging the proximal hub from the core member tube to allow rapid collapse of the elongate members from the expanded configuration.
In accordance with still another embodiment, a brachytherapy treatment apparatus is provided that includes an elongate body including a proximal end and a distal end configured for introduction into a tract through tissue; a plurality of elongate members on the distal end including pathways for receiving a source of radiation therealong, the elongate members being movable from a collapsed configuration for introduction through a tissue tract to a target location, and an expanded configuration; and a plurality of marker devices removably receivable along the pathways of respective elongate members.
In accordance with yet another embodiment, a method is provided for brachytherapy treatment of tissue within a body that includes creating a tract through tissue to a target location including a cavity, and advancing an elongate body carrying a plurality of elongate members through the tract into the target location with the elongate members in a collapsed configuration. The elongate members may be directed to an expanded configuration at the target location to position the elongate members away from a central axis such that tissue in the target region (e.g., surrounding the cavity) extends between at least a portion of adjacent elongate members, and radiation may be delivered to the target location to treat tissue at the target location.
In accordance with still another embodiment, a method for brachytherapy treatment of tissue within a body is provided. A tract may be created through tissue to a target location adjacent to a cavity, and an elongate body carrying a plurality of elongate members may be advanced through the tract into the target location with the elongate members in a collapsed configuration. The elongate members may be directed to an expanded configuration at the target location to position the elongate members away from a central axis, and marker devices may be inserted into the elongate members, e.g., before or after being expanded. The apparatus may be imaged, e.g., using CT or ultrasound, the marker devices enhancing imaging of the elongate members in the expanded configuration relative to the target location. A dose plan may be developed based at least on part on the enhanced imaging of the elongate members, and the marker devices may be removed from the elongate members. Radiation may be delivered to the target location to treat tissue at the target location according to the dose plan.
The above summary is not intended to describe each embodiment or every implementation of the present invention. Rather, a more complete understanding of the invention will become apparent and appreciated by reference to the following detailed description and claims in view of the accompanying drawings.
Generally speaking, the present invention is directed to brachytherapy apparatus, systems, and methods. For example, in one embodiment, a system is provided for delivering one or more therapeutic elements (e.g., radiation sources) relative to a target tissue region. Once delivered, the radiation sources may be either immediately withdrawn (e.g., in HDR applications), or left in place, e.g., implanted, for a defined period of time (e.g., in LDR applications). In either instance, the radiation sources may deliver therapy to the target tissue region in accordance with a predefined therapy profile.
In some embodiments, LDR radiation sources may be implanted and secured to the body or target tissue in such a way as to prevent or substantially limit movement of the sources relative to the target tissue. For example, the apparatus and methods described herein may facilitate indwelling therapy using pre-arranged packages of radioactive sources, e.g., seeds, but also allow easy removal of the radiation sources upon completing brachytherapy treatment.
As used herein, “radiation source” and “radioactive source” may include any therapeutic element operable to deliver a dose of radiation. For example, the radiation source may be one or more radioactive seeds or, alternatively, one or more LDR or HDR wire elements (e.g., Iridium wire), e.g., as disclosed in application Ser. Nos. 10/658,518, filed Sep. 9, 2003, and published as US 2004/0116767; 11/554,731, filed Oct. 31, 2006, and published as US 2007/167664; 11/276,851, filed Mar. 16, 2006, and published as US 2007/0106108; 11/557,747, filed Nov. 8, 2006, and published as US 2007/167665, and 11/757,231, filed Jun. 1, 2007. The entire disclosures of these applications are expressly incorporated by reference herein.
The term “implantable,” as used herein, indicates the capability of a device to be inserted into the body and then maintained in a relatively fixed or static position within the surrounding tissue for an extended period of time, e.g., an hour or more and/or several hours or more, including several days or more.
Furthermore, “target tissue,” “target tissue region,” “target region,” and “target tissue volume,” as used herein, may include any portion of a human (or other mammalian) body that has been identified to benefit from radiation therapy. For example, the target tissue region may be a tumor or lesion itself, tissue proximate or surrounding the tumor, or a cavity region created by tumor excision (such as the surrounding tissue or cavity associated with a lumpectomy cavity of the breast).
It should be noted that the apparatus, systems, and methods described herein may be used for LDR or HDR brachytherapy, as described elsewhere herein and in the applications incorporated by reference above. Moreover, while described herein with respect to brachytherapy, the apparatus, systems, and methods may apply to other therapy regimens that benefit from the removable implantation of therapy-delivering elements. In an exemplary application, the apparatus, systems, and methods are described herein for treating breast cancer. However, it will be appreciated that the apparatus, systems, and methods described herein may be used for treating other cancers or conditions that may benefit from brachytherapy treatment.
Turning to
In addition, as shown in
With additional reference to
The elongate members 30 may be elongate tubular members including a proximal end 32, a distal end 34, and a lumen 36 extending therebetween (shown in
The elongate members 30 may be formed from a single extrusion separated to provide the set of elongate members 30, individual extrusions or other tubular bodies, or may be formed from multiple tubular bodies connected to one another, e.g., by bonding, fusing, lapping, and the like. The elongate members 30 may also include an intermediate portion 33 that is attached to or otherwise secured relative to the proximal hub 22. For example, the intermediate portion 33 may be securely received between an outer collar 23 and an inner main tube hub 22a of the proximal hub 22, e.g., using an interference fit, bonding with adhesive, sonic welding, and the like.
The proximal hub 22 may be provided from a single piece, e.g., such that the outer collar 23 and inner main tube hub 22a are integrally molded or otherwise formed together. Alternatively, the proximal hub 22 may be formed from separate components that are attached together, e.g., using an interference fit, cooperating connectors, bonding using an adhesive, sonic welding, and the like. Optionally, the proximal hub 22 may include individual axial openings for receiving the intermediate portions 33 of respective elongate members 30 therethrough. Alternatively, the elongate members 30 may extend from the distal hub 24 to the proximal hub 22, and terminate within or adjacent the proximal hub 22. In this alternative, separate tubular members (not shown) may be provided that are attached to the elongate members 30 and/or proximal hub 22 to provide the proximal portion 12 of the apparatus 10, while still providing lumens 36 extending from the proximal portion 12 to the distal portion 14.
The distal ends 34 of the elongate members 30 may be received within and/or secured to the distal hub 24. For example, the distal hub 24 may include an annular recess or individual pockets into which the distal ends 34 may be received and secured, e.g., using an interference fit, bonding with an adhesive, sonic welding, and the like. The distal hub 24 may provide a rounded and/or tapered distal tip for the apparatus 10, e.g., to facilitate introduction into a patient's body. Alternatively, the distal hub 24 may include a pointed or other sharpened distal tip (not shown) for facilitating advancing the apparatus 10 directly through tissue (not shown).
Optionally, the distal hub 24 may be formed from radiolucent material, e.g., non-metallic material such as glass-filled nylon combined with isoprene rubber. If the distal hub 24 is formed from radiolucent material, radiopaque markers, such as the marker device 80 shown in
In addition, as shown in
Alternatively, the supports 40 may be provided within an additional lumen (not shown) within the elongate members 30, similar to embodiments disclosed in the applications incorporated by reference above. In a further alternative, the supports 40 may be eliminated. For example, the elongate members 30 may be configured, e.g., may have asymmetrical cross-sections, to bias the elongate members 30 to expand radially in a predetermined manner, as disclosed in the applications incorporated by reference above. Optionally, the supports 40 may provide shielding, in addition to or instead of supporting the elongate members 30, also as disclosed in the applications incorporated by reference above.
In an exemplary embodiment, as shown in
Optionally, a locking ring 22d (shown only partially in
The supports 40 may be oriented such that their major dimension is disposed generally circumferentially relative to the core member 20 and their minor dimension is disposed generally radially. In the collapsed configuration, the supports 40 may extend substantially axially, i.e., substantially parallel to the core member 20. As described further below, when the proximal and distal hubs 22, 24 are directed towards one another, the supports 40 may bow radially outwardly between the proximal and distal ends 42, 44, thereby controlling expansion of the elongate members 30 as they are directed towards the expanded configuration.
Turning to
As shown, the distal end 64 of the distal tube 60 is received within the distal hub 24. The distal end 64 may be secured to the distal hub 24, e.g., using an interference fit, cooperating connectors, bonding using an adhesive, sonic welding, and the like. Thus, the distal tube 60 may remain substantially stationary relative to the distal hub 64 and the distal ends 34 of the elongate members 30.
The proximal end 62 of the distal tube 60 includes internal threads 63 extending for a predetermined distance along the length of the proximal end 62. Thus, the proximal end 62 may also include an unthreaded region distal to the internal threads 63. The distal tube 60 may be formed as a single tubular segment extending between the proximal and distal ends 62, 64, thereby defining a lumen 66. Alternatively, the distal tube 60 may be formed from multiple segments attached to one another. For example, the distal tube 60 may include a first tubular segment defining the proximal end 62, e.g., including the internal threads 63 and the unthreaded region, and a second segment extending from the proximal end 62 to the distal end 64. The first and second segments may be attached to one another, e.g., using mating threads or other cooperating connectors, interference fit, bonding using an adhesive, welding, sonic welding, and the like. The second segment may be a tubular or solid rod segment, depending upon whether it is desired to extend the lumen 66 from the proximal end 62 entirely to the distal end 64.
The proximal tube 50 also includes a lumen 56 extending between the proximal and distal ends 52, 54. The lumen 56 may communicate with the lumen 66 in the distal tube 60, e.g., if it is desired to introduce a radiation source or other device through the core member 20 at least partially towards the distal hub 24. The proximal tube 50 may be slidably disposed within or otherwise received through the proximal hub 22, as shown in
In addition, the proximal tube 50 may include a stop, e.g., an annular rib 53, radial tabs (not shown), and the like on the proximal end 52 disposed proximal and adjacent to the proximal hub 22, as best seen in
With particular reference to
Turning to
As best seen in
This configuration of the threads 55, 63 may also prevent overexpansion of the elongate members 30. Once the threads 55, 63 disengage, the proximal tube 50 may not be directed distally further, thereby preventing further distal movement of the proximal hub 22. Thus, the relative length and location of the external and internal threads 55, 63 may be selected to provide a desired size and/or shape for the elongate members 30 in the expanded configuration. Optionally, the distal tube 60 may include a stop, e.g., an end wall (not shown), that prevents further distal movement of the proximal tube 50 when the distal end 54 enters the unthreaded region. This may prevent the user from forcing the proximal tube 50 further distally, which may over-expand and/or damage the elongate members 30 and/or supports 40.
When it is desired to collapse the elongate members 30, the proximal tube 50 may be rotated in a second opposite direction, e.g., counterclockwise. The external threads 55 may reengage the internal threads 63, and then thread the external threads 55 proximally, thereby directing the proximal hub 22 proximally. As the proximal hub 22 is directed proximally, the elongate members 30 and supports 40 may be pulled back radially inwardly towards the collapsed configuration, as shown in
Optionally, as best seen in
During use, the expansion tool 70 may be inserted between the elongate members 40 and engaged with the connector(s) on the proximal end 52 of the proximal tube 50 of the core member 20. Optionally, as shown in
The expansion tool 70 may be advanced until the distal end 74 engages with the proximal end 52 of the proximal tube 50 of the core member 20 (see
The apparatus 10 may be used for brachytherapy treatment within a tissue structure, for example within a breast (not shown). The breast may have a cavity (e.g., a lumpectomy cavity) formed therein by removal of cancerous tissue (also not shown). The apparatus 10 may be inserted in its collapsed position into the breast or other tissue structure. The apparatus 10 may be inserted via an existing incision (not shown), e.g., the incision used to perform the lumpectomy, or via a new incision created for delivering the apparatus 10.
During use, the apparatus 10 may be provided with the elongate members 30 in the collapsed configuration, as shown in
The expansion tool 70 may then be rotated in a first direction to direct the proximal hub 2 distally relative to the distal hub 24, thereby causing the elongate members 30 to bow outwardly within the cavity, as shown in
Optionally, thereafter, the apparatus 10 may be secured relative to the target tissue region to prevent subsequent migration. Alternatively, the elongate members may sufficiently engage the surrounding tissue to prevent substantial migration. If the apparatus 10 is to remain within the target tissue region for an extended period of time, the expansion tool 70 may be removed from the apparatus 10.
One or more radiation sources (not shown) may then be directed into the lumens 36 of the elongate members 30 to deliver radiation to the tissue surrounding the cavity. Thus, the elongate members 30 may define pathways for receiving radiation source(s). If the core member 20 includes a lumen, one or more radiation sources may also be directed into the lumen of the core member 20. Alternatively, the elongate members 30 and/or core member 20 may include other features providing pathways extending between the proximal and distal portions 12, 14 of the apparatus 10. For example, the elongate members 30 may include grooves or tracks (not shown), which may receive one or more sources of radiation, as described in the applications incorporated by reference above.
In an exemplary procedure, a plurality of LDR sources may be delivered into the elongate members 30 and/or core member 20, and remain indwelling for a predetermined time. For example, individual seeds, pods of seeds, or other radiation sources may be loaded into respective elongate members 40 simultaneously or sequentially, thereby providing a three dimensional array of seeds or other radiation sources that may remain in the target location for an extended period of time. The seeds may be spaced apart on each pod or have different radioactive intensities, according to the dose plan. For example, the seeds in different portions of the array may also have different lengths and/or spacing along respective elongate members 10 such that the array is substantially asymmetrical, e.g., radially and/or axially relative to a central axis of the apparatus 10.
Alternatively, one or more HDR sources may be delivered sequentially or simultaneously into the elongate members 30 and/or core member 20 according to a desired dose plan, as described elsewhere herein. For example, an HDR source may be introduced into a first elongate member 30, advanced to a first position, and maintained at the first position for a predetermined time. The HDR source may then be advanced and/or retracted to a second position, and maintained there for a predetermined time, etc. The HDR source may then be removed from the first elongate member 30, and then introduced sequentially into each of the other elongate members 30 in a similar manner. In a further alternative, one or more radiation sources may be preloaded or secured within the elongate members 30 before introduction into the cavity. Additional information on use of the apparatus 10 may be found in the applications incorporated by reference above.
Upon completion of the brachytherapy treatment, the apparatus 10 may be returned to its collapsed configuration, and the apparatus 10 removed from the breast via the insertion incision. For example, if the expansion tool 70 has been removed, the expansion tool 70 may be introduced and reconnected to the proximal tube 50. The expansion tool 70 may then be rotated to rotate the proximal tube 50 of the core member 20 and collapse the elongate members 30 back to the collapsed configuration, as described elsewhere herein.
Before treating the patient, it may be desirable to create a dose plan to determine the course of treatment. Dose planning may be accomplished using a variety of imaging methods (e.g., CT or ultrasound) and/or using dose planning software for either HDR or LDR applications. The timing and general scenario of the dose planning process is at the discretion of the clinical physicist/oncologist. However, one such scenario may include placing the apparatus 10 into the target tissue region and actuating the distal portion 14 into the deployed configuration. Then, with the aid of imaging (e.g., CT), both the target tissue region and the position of the elongate members 30 may be delineated. A dose plan may then be developed and, if desired, modified as configuration adjustments are made to the apparatus 10 and/or the elongate members 30.
To assist with dose planning, it may be desirable to provide one or more marker devices, e.g., within the lumens of the elongate members 30. The marker devices may be provided from radiopaque or other materials that create an artifact or are otherwise detectable using the imaging device to identify the relative location and/or orientation of the elongate members 30.
The marker device 80 may have a length corresponding to the length of the elongate members 30, e.g., at least as long as the elongate members 30. For example, as shown in
Thereafter, the radiopacity of the marker devices 80 may enhance monitoring the location and/or orientation of the elongate members 30 by identifying the marker devices 80. For example, the marker devices 80 may delineate the entire path for an HDR catheter, e.g., using x-ray or other imaging modalities, such as CT. The distal ends 84 of the marker devices 80 may also be used to help identify an initial dwell position of an HDR source introduced sequentially into the elongate members 30 (after removing the marker devices 80). Optionally, one or more radiopaque markers, e.g., a gold or other band (not shown), may be provided on the distal end 84, e.g., by crimping, welding, bonding, and the like to enhance radiopacity of the distal end 84.
When the dose plan is optimized, the characteristics of the radioactive sources (e.g., brachytherapy devices) are chosen (e.g., LDR seed activity levels, HDR dwell positions and/or times, etc.), and prepared for placement into the apparatus 10 via the openings in the proximal ends 32 of the elongate members 30. The marker devices 80 may then be removed before treatment.
The marker devices 80 may also support the elongate members 30. For example, a cable may provide a relatively strong yet flexible support that may be inserted into the elongate members 30 between treatments. Thus, the marker devices 80 may prevent kinking or other deformation or damage to the elongate members 30 between treatments, e.g., for HDR therapies.
Optionally, the marker device 80 may be used to seal the lumen 36 of an elongate member 30, e.g., to prevent fluid, debris, and the like from entering. As shown, the marker device 80 may include an end cap 86 on the proximal end 82, which may be seated over or otherwise seal the proximal end 32 of an elongate member 30. For example, between treatments, a marker device 80 may be inserted into each of the elongate members 30 of the apparatus 10, e.g., as shown in
The end cap 86 may extend distally beyond the spacer 88, thereby defining an annular pocket for receiving the proximal end 32 of an elongate member 30. The end cap 86 may be sized to frictionally engage the proximal end 32 received between the end cap 86 and the proximal end 82, thereby substantially sealing the lumen of the elongate member 30.
Turning to
For example,
Thus, the retaining ring 58 may prevent axial movement of the proximal hub 22 and proximal tube 50 relative to one another. However, because of the ramped edge 52b, if sufficient axial force is applied, e.g., by pulling the proximal hub 22 relative to the proximal tube 50, the retaining ring 58 may elastically stretch and/or plastically deform allowing the retaining ring 58 to be directed up the ramped edge 52b. For example, the expansion tool 70 (not shown) may be coupled to the proximal tube 50, and the proximal hub 22 pulled proximally while preventing movement of the expansion tool 70. This may cause the proximal edge 25 to push the retaining ring 58 up the ramped edge 52b, thereby causing the retaining ring 58 to expand radially as it passes over the ramped edge 52b.
Once the retaining ring 58 passes beyond the ramped edge 52b, the retaining ring 58 may be released, thereby allowing the proximal hub 22 to be directed proximally relative to the proximal tube 50, thereby pulling the elongate members 30, e.g., towards the collapsed configuration. For example, the retaining ring 58 may be plastically deformed to a sufficiently large size that the retaining ring 58 no longer bears against the proximal tube 50. Alternatively, the retaining ring 58 may expand and break or otherwise yield as it passes over the ramped edge 52b. Thus, with a rapid, relatively high force (compared to normal use of the apparatus 10), the proximal hub 22 may be disengaged from the proximal tube 50 and allow rapid collapse of the elongate members 30.
Turning to
Exemplary embodiments of the present invention are described above. Those skilled in the art will recognize that many embodiments are possible within the scope of the invention. Other variations, modifications, and combinations of the various components and methods described herein can certainly be made and still fall within the scope of the invention. For example, any of the treatment devices described herein may be combined with any of the delivery systems and methods also described herein. Thus, the invention is limited only by the following claims, and equivalents thereto.
This application claims benefit of co-pending provisional application Ser. No. 60/828,655, filed Oct. 8, 2006, the entire disclosure of which is expressly incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3060924 | Rush | Oct 1962 | A |
3750653 | Simon | Aug 1973 | A |
3968803 | Hyman | Jul 1976 | A |
4427005 | Tener | Jan 1984 | A |
4580561 | Williamson | Apr 1986 | A |
4714074 | Rey et al. | Dec 1987 | A |
4798212 | Arana | Jan 1989 | A |
4936823 | Colvin et al. | Jun 1990 | A |
4957476 | Cano | Sep 1990 | A |
4976680 | Hayman et al. | Dec 1990 | A |
5056523 | Hotchkiss, Jr. et al. | Oct 1991 | A |
5106360 | Ishiwara et al. | Apr 1992 | A |
5152741 | Farnio | Oct 1992 | A |
5235966 | Jamner | Aug 1993 | A |
5242372 | Carol | Sep 1993 | A |
5279565 | Klein et al. | Jan 1994 | A |
5302168 | Hess | Apr 1994 | A |
5336178 | Kaplan et al. | Aug 1994 | A |
5354257 | Roubin et al. | Oct 1994 | A |
5411466 | Hess | May 1995 | A |
5423747 | Amano | Jun 1995 | A |
5429605 | Richling et al. | Jul 1995 | A |
5503613 | Weinberger | Apr 1996 | A |
5509900 | Kirkman | Apr 1996 | A |
5538502 | Johnstone | Jul 1996 | A |
5540659 | Teirstein | Jul 1996 | A |
5611767 | Williams | Mar 1997 | A |
5653683 | D'Andrea | Aug 1997 | A |
5678572 | Shaw et al. | Oct 1997 | A |
5707332 | Weinberger | Jan 1998 | A |
5713828 | Coniglione | Feb 1998 | A |
5720717 | D'Andrea | Feb 1998 | A |
5730698 | Fischell et al. | Mar 1998 | A |
5782740 | Schneiderman | Jul 1998 | A |
5840008 | Klein et al. | Nov 1998 | A |
5843163 | Wall | Dec 1998 | A |
5851171 | Gasson | Dec 1998 | A |
5863284 | Klein | Jan 1999 | A |
5882291 | Bradshaw et al. | Mar 1999 | A |
5891091 | Teirstein | Apr 1999 | A |
5910102 | Hastings | Jun 1999 | A |
5913813 | Williams et al. | Jun 1999 | A |
5916143 | Apple et al. | Jun 1999 | A |
5931774 | Williams et al. | Aug 1999 | A |
5938582 | Ciamacco, Jr. et al. | Aug 1999 | A |
5942209 | Leavitt et al. | Aug 1999 | A |
5976106 | Verin et al. | Nov 1999 | A |
6013019 | Fischell et al. | Jan 2000 | A |
6022308 | Williams | Feb 2000 | A |
6033357 | Ciezki et al. | Mar 2000 | A |
6036632 | Whitmore et al. | Mar 2000 | A |
6056722 | Jayaraman | May 2000 | A |
6059752 | Segal | May 2000 | A |
6071263 | Kirkman | Jun 2000 | A |
6074339 | Gambale et al. | Jun 2000 | A |
6083148 | Williams | Jul 2000 | A |
6117064 | Apple et al. | Sep 2000 | A |
6159139 | Chiu | Dec 2000 | A |
6159141 | Apple et al. | Dec 2000 | A |
6176821 | Crocker et al. | Jan 2001 | B1 |
6179766 | Dickerson | Jan 2001 | B1 |
6196996 | Teirstein | Mar 2001 | B1 |
6200256 | Weinberger | Mar 2001 | B1 |
6200257 | Winkler | Mar 2001 | B1 |
6213976 | Trerotola | Apr 2001 | B1 |
6217585 | Houser et al. | Apr 2001 | B1 |
6221003 | Sierocuk et al. | Apr 2001 | B1 |
6221030 | Avaltroni | Apr 2001 | B1 |
6234951 | Hastings | May 2001 | B1 |
6238374 | Winkler | May 2001 | B1 |
6258099 | Mareiro et al. | Jul 2001 | B1 |
6261320 | Tam et al. | Jul 2001 | B1 |
6264599 | Slater et al. | Jul 2001 | B1 |
6264631 | Willis et al. | Jul 2001 | B1 |
6267775 | Clerc et al. | Jul 2001 | B1 |
6287249 | Tam et al. | Sep 2001 | B1 |
6338709 | Geoffrion | Jan 2002 | B1 |
6358195 | Green et al. | Mar 2002 | B1 |
6371904 | Sirimanne et al. | Apr 2002 | B1 |
6458069 | Tam et al. | Oct 2002 | B1 |
6482178 | Andrews et al. | Nov 2002 | B1 |
6494824 | Apple et al. | Dec 2002 | B1 |
6506145 | Bradshaw et al. | Jan 2003 | B1 |
6508784 | Shu | Jan 2003 | B1 |
6527692 | Weinberger | Mar 2003 | B1 |
6527693 | Munro, III et al. | Mar 2003 | B2 |
6540656 | Fontayne et al. | Apr 2003 | B2 |
6540734 | Chiu et al. | Apr 2003 | B1 |
6554757 | Geitz | Apr 2003 | B1 |
6582353 | Hastings et al. | Jun 2003 | B1 |
6589158 | Winkler | Jul 2003 | B2 |
6592548 | Jayaraman | Jul 2003 | B2 |
6607476 | Barnhart | Aug 2003 | B1 |
6607478 | Williams | Aug 2003 | B2 |
6638206 | Green et al. | Oct 2003 | B2 |
6641518 | Wolfson et al. | Nov 2003 | B2 |
6645135 | Bhat | Nov 2003 | B1 |
6648811 | Sierocuk et al. | Nov 2003 | B2 |
6659933 | Asano | Dec 2003 | B2 |
6673006 | Winkler | Jan 2004 | B2 |
6676667 | Mareiro et al. | Jan 2004 | B2 |
6685619 | Halpern et al. | Feb 2004 | B2 |
6692460 | Jayaraman | Feb 2004 | B1 |
6699170 | Crocker et al. | Mar 2004 | B1 |
6746465 | Diederich et al. | Jun 2004 | B2 |
6752752 | Geitz | Jun 2004 | B2 |
6752753 | Hoskins et al. | Jun 2004 | B1 |
6910999 | Chin et al. | Jun 2005 | B2 |
6923754 | Lubock | Aug 2005 | B2 |
6955641 | Lubock | Oct 2005 | B2 |
7041047 | Gellman et al. | May 2006 | B2 |
7056276 | Nakano et al. | Jun 2006 | B2 |
7357770 | Cutrer et al. | Apr 2008 | B1 |
20010007071 | Koblish | Jul 2001 | A1 |
20020016583 | Cragg | Feb 2002 | A1 |
20020032359 | Geoffrion et al. | Mar 2002 | A1 |
20020165427 | Yachia et al. | Nov 2002 | A1 |
20030092957 | Scott et al. | May 2003 | A1 |
20030114878 | Diederich et al. | Jun 2003 | A1 |
20030158515 | Gonzalez et al. | Aug 2003 | A1 |
20030163017 | Tam et al. | Aug 2003 | A1 |
20030236443 | Cespedes et al. | Dec 2003 | A1 |
20040006305 | Hebert et al. | Jan 2004 | A1 |
20040068231 | Blondeau | Apr 2004 | A1 |
20040087828 | Green et al. | May 2004 | A1 |
20040116767 | Lebovic et al. | Jun 2004 | A1 |
20040127765 | Seiler et al. | Jul 2004 | A1 |
20040260142 | Lovoi | Dec 2004 | A1 |
20050061533 | Lovoi | Mar 2005 | A1 |
20050075662 | Pedersen et al. | Apr 2005 | A1 |
20050080313 | Stewart et al. | Apr 2005 | A1 |
20050090845 | Boyd | Apr 2005 | A1 |
20050096647 | Steinke et al. | May 2005 | A1 |
20050101823 | Linares et al. | May 2005 | A1 |
20050101860 | Patrick et al. | May 2005 | A1 |
20050124843 | Singh | Jun 2005 | A1 |
20050182286 | Lubock | Aug 2005 | A1 |
20050240074 | Lubock | Oct 2005 | A1 |
20060015166 | Kindlein et al. | Jan 2006 | A1 |
20060020156 | Shukla | Jan 2006 | A1 |
20060094923 | Mate | May 2006 | A1 |
20060100475 | White et al. | May 2006 | A1 |
20060116546 | Eng | Jun 2006 | A1 |
20060173233 | Lovoi | Aug 2006 | A1 |
20060173235 | Lim et al. | Aug 2006 | A1 |
20060184192 | Markworth et al. | Aug 2006 | A1 |
20060199990 | Rioux et al. | Sep 2006 | A1 |
20060235365 | Terwilliger et al. | Oct 2006 | A1 |
20060258895 | Maschke | Nov 2006 | A1 |
20070106108 | Hermann et al. | May 2007 | A1 |
20070142694 | Cutrer et al. | Jun 2007 | A1 |
20070167664 | Hermann et al. | Jul 2007 | A1 |
20070167667 | Lubock et al. | Jul 2007 | A1 |
20070191668 | Lubock et al. | Aug 2007 | A1 |
20080091055 | Nguyen | Apr 2008 | A1 |
Number | Date | Country |
---|---|---|
0318447 | Sep 1994 | EP |
0390528 | Jan 1997 | EP |
0775505 | May 1997 | EP |
0536888 | Jan 1998 | EP |
0955071 | Nov 1999 | EP |
0884977 | Apr 2003 | EP |
0782410 | Dec 2003 | EP |
1402922 | Mar 2004 | EP |
0808129 | May 2004 | EP |
1428477 | Jun 2004 | EP |
1568397 | Aug 2005 | EP |
0195808 | Dec 2001 | WO |
03079907 | Oct 2003 | WO |
2005037363 | Apr 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20080091055 A1 | Apr 2008 | US |
Number | Date | Country | |
---|---|---|---|
60828655 | Oct 2006 | US |